Fig. 7: PrEXO-a23 effectively decreases the risk of CAC and fibrosis.
From: Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease
a Schematic illustration of the protein-protein interaction network analysis for identifying Trp53 in PrEXO-a23 treatment. Created in BioRender. Zhang, F. (2026) https://BioRender.com/rx9bdp9. b Diagram of treatment schedule for PrEXO-a23 in AOM/DSS-induced CAC mouse model. c, d Survival curves (c) and DAI score (d) in CAC mice receiving indicated treatments. e–g, Photos (e), tumor burden (f), and tumor number (g) of colons in CAC mice at week 10. h, i ELISA quantification of TNF-α (h) and IL-6 (i) in colon tissue. j H&E-stained histological images of colon sections in CAC mice. Scale bar, 250 μm. k Representative Ki67-stained images of colon sections. Green: Ki67; Blue: nucleus; Scale bar, 100 μm. l H&E-stained histological images of colon sections in intestinal fibrosis mice. Scale bar, 100 μm. m–o Thickness of colonic wall (m), muscularis propria (n), and muscularis mucosa (o) of colonic section in mice. p, q Representative immunohistochemical staining images (p) and quantification (q) for α-SMA in colon sections. Scale bar, 100 μm. For (j–l, p), experiment was repeated three times independently with similar results. For (c, d, f–i, m–o, q), data were presented as mean ± SD (n = 8 mice in c; n = 4 mice in d, f, g; n = 3 mice in h, i, m–o, q). For (f–i, m–o, q), statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test. P value for the survival data (c) was analyzed using the log-rank (Mantel–Cox) test. Source data are provided as a Source Data file.
